3. Walsh, E. E. et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med 383, 2439–2450 (2020). 4. Hammond, J. et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19...
7. Falsey, A.R., et al.,Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.N Engl J Med, 2021.385(25): p. 2348-2360. 8. Sadoff, J., et al.,Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.N Engl J Med, 2021.384(23): p...
chemical modification of mRNA is only one of them,” says Bo Ying, chief executive of Suzhou Abogen Biosciences, a Chinese company with an mRNA vaccine for COVID-19 now in late-stage clinical testing. (Known as ARCoV, the product uses unmodified mRNA.) ...
in a cruel irony, they are also at high risk of severe COVID-19 complications, suggesting that they would greatly benefit from vaccine-mediated protection. In an effort to cast more light on the safety of mRNA-based COVID-19 vaccines, a...
Our results would suggest that these recipients of Ad26.COV2.S vaccines may benefit from additional mRNA vaccine doses with the potential to further raise titers and broaden their neutralizing activity. Several reports have measured the decay of neutralizing antibody responses raised by mRNA COVID-...
47、 Leal, L. et al. Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection. AIDS 32, 2533–2545 (2018). 48、 Tomas, K. U.S. COVID vaccine supply: how to make sense of those confusing numbers. The New York Times. https://www...
2023年10月2日下午5点45分,2023年诺贝尔生理学或医学奖花落卡塔林·卡里科(Katalin Karikó)和德鲁·维斯曼(Drew Weissman),他们因为研发的mRNA技术,推动COVID-19 的 mRNA 疫苗发展而获奖。 如果没有新冠疫情大暴发,该技术在人类的应用可能还要...
Figure 1. Cases of Myocarditis After mRNA-Based COVID-19 Vaccination by Age at Onset of Myocarditis View LargeDownload The reports to the Vaccine Adverse Event Reporting System met the case definition of myocarditis (reported cases). Among individuals older than 40 years of age, there were no ...
COVID-19基因疫苗的成功启发了许多季节性流感疫苗的临床试验,其中大多数疫苗编码流感病毒HA抗原。然而,由于HA抗原的抗原漂移和/或移位,疫苗株与流行病毒株之间可能发生抗原错配,这给当前流感疫苗的生产和应用带来了挑战。因此,迫切需要一种能够对不同流感病毒具有广谱保护作用的流感疫苗。
[8]Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models. [9]Control of the neuroprotective Lipocalin Apolipoprotein D expression by alternative promoter regions and differentially expressed mRNA 5' UTR variants ...